๐ฐ Leukemia News
Page 158 - Leukemia News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.
June 14, 2022
On November 23, 2021, former South Korean President Chun Doo-hwan died at the age of 90. According to ...
June 14, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
June 13, 2022
The 11-year-old, now cleared to travel, wants to make memories outside of the hospital and has decided she wants to take her family, of eight to Disney World.
June 13, 2022
Pinkel faced much hostility for his treatments of child patients, for instance, โDonโt give those poisons; let the children die in peaceโ
June 13, 2022
Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers.
June 10, 2022
A new researchโโ describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications -the so-called epigenetics- of a type of its genetic material: the messenger RNA.
June 10, 2022
SOUTH SAN FRANCISCO (dpa-AFX) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic
June 9, 2022
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic
June 7, 2022
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
June 7, 2022
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).